PDE8B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6909462	1.00	20/20
SCHEMBL6909468	1.00	20/20
SCHEMBL6909572	1.00	20/20
SCHEMBL6910428	1.00	20/20
SCHEMBL6910576	1.00	20/20
SCHEMBL6910585	1.00	20/20
SCHEMBL6910604	1.00	20/20
SCHEMBL6910946	1.00	20/20
SCHEMBL6910951	1.00	20/20
SCHEMBL6911014	1.00	20/20
SCHEMBL6911420	0.83	20/20
SCHEMBL6911029	0.81	20/20
SCHEMBL6910351	0.77	20/20
SCHEMBL6909200	0.77	20/20
SCHEMBL6909220	0.77	20/20
SCHEMBL6910920	0.77	20/20
SCHEMBL6909224	0.72	20/20
SCHEMBL6909028	0.72	20/20
SCHEMBL6910407	0.72	20/20
SCHEMBL6909035	0.71	20/20

Clinical trials — most relevant to PDE8B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Switching of Sildenafil to Riociguat in CTEPH Patients	PHASE4	RECRUITING
Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness	PHASE4	COMPLETED
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Clinical Trial Using Topically Applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction	PHASE3	COMPLETED
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)	PHASE3	COMPLETED
Tadalafil as Adjuvant Therapy for DMD	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)	PHASE1/PHASE2	COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction	PHASE2	COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals	PHASE1/PHASE2	COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease	PHASE2	COMPLETED
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)	PHASE2	COMPLETED
Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary	PHASE2	COMPLETED
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients	PHASE1/PHASE2	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease	PHASE1	COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram	PHASE1	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN
Endurance Performance at Altitude	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children	nan	COMPLETED
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.	nan	UNKNOWN
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PDE8B binder may also engage these)

Protein	Name	Similarity
E9Q4S1	—	1.000	E9Q4S1 →
PDE8A	High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A	1.000	landscape →
O88502	—	1.000	O88502 →
P30645	—	0.997	P30645 →
O70628	—	0.997	O70628 →
Q8I0P7	—	0.994	Q8I0P7 →
O14827	—	0.994	O14827 →
PDE9A	High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A	0.994	landscape →
G5EFD2	—	0.993	G5EFD2 →
Q9H1H9	—	0.993	Q9H1H9 →
Q95RG8	—	0.993	Q95RG8 →
A1ZAJ2	—	0.993	A1ZAJ2 →
I2HAA0	—	0.993	I2HAA0 →
Q9W3D3	—	0.993	Q9W3D3 →
Q9N2V9	—	0.993	Q9N2V9 →
B0R0W9	—	0.992	B0R0W9 →
Q9AWM8	—	0.992	Q9AWM8 →
P70392	—	0.992	P70392 →
Q7Z401	—	0.992	Q7Z401 →
P25799	—	0.992	P25799 →
Q8QZV1	—	0.992	Q8QZV1 →
KAT8	Histone acetyltransferase KAT8	0.992	landscape →
Q22908	—	0.992	Q22908 →
O12990	—	0.992	O12990 →
P54936	—	0.992	P54936 →
P43125	—	0.992	P43125 →
H2KZW3	—	0.992	H2KZW3 →
I1MGE5	—	0.992	I1MGE5 →
Q19546	—	0.991	Q19546 →
Q9XTJ4	—	0.991	Q9XTJ4 →